HealthQuill Merck & Co
Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a secondary goal of a ‘high’ viral suppression rate in adults.
Drugs Health Pharma

Gilead, Merck’s HIV experimental drug scores ‘high’ on viral suppression

Merck & Co., Inc., and Gilead Sciences, Inc.’s investigational combinational drug for HIV treatment, put on clinical hold last year, has met a.

Read More
https://www.merck.com/product/usa/pi_circulars/g/gardasil_9/gardasil_9_ppi.pdf
Drugs Health Pharma

Merck meets main goal during end-stage trial of HPV vaccine in Japan

Merck & Co., announced it has met its primary and secondary goals during the end-stage trials of its human papillomavirus (HPV) vaccine in.

Read More
Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%, the latest results of the company's trials reveal.
Drugs Health Pharma

Summit’s lung cancer drug reduces risk of disease progression by 48%

Summit Therapeutics Inc.’s investigational drug ivonescimab helps lung cancer patients to cut the risk of progression or death from the disease by 48%,.

Read More
Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in 27 member states and other nations.
Drugs Health Pharma

EC approves Merck’s bladder cancer combination therapy in adults 

Merck & Co., got approval from the European Commission to market its combination therapy to treat metastatic urothelial cancer or bladder cancer in.

Read More
Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated the drug wouldn’t succeed.
Drugs Health Pharma

Merck halts small cell lung cancer immunotherapy drug trial

Merck has stopped an end-stage combination immunotherapy trial for a lung cancer condition, following recommendations of an independent data monitoring committee, which indicated.

Read More
https://www.merck.com/news/daiichi-sankyo-and-merck-enter-into-global-development-and-commercialization-agreement-for-mk-6070/
Drugs Health Pharma

Daiichi Sankyo to pay Merck $170 million for cancer test drug rights

Daiichi Sankyo will pay Merck & Co. Inc., $170 million upfront to bag commercialization and development rights of the latter’s test drug for.

Read More
Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment of Merck & Co.
Drugs Health Pharma

Roche ends small cell lung cancer trials as results show ‘reduced efficacy’

Swiss drugmaker, Roche, halted a lung cancer trial after it failed to meet the goal of progression-free survival compared to an existing treatment.

Read More
The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat a type of lung cancer.
Drugs Health Pharma

FDA rejects Daiichi, Merck, antibody-drug conjugate application

The USFDA has rejected a Biologics License Application from Daiichi Sankyo and Merck & Co., seeking accelerated approval of patritumab deruxtecan to treat.

Read More
The US regulator, the Food and Drug Administration, has approved Winrevair therapy of Merck & Co., Inc., to treat pulmonary arterial hypertension.
Drugs Health Pharma

US regulator clears Merck’s lung therapy after ‘significant’ results

 HQ Team March 27, 2024: The US regulator, the Food and Drug Administration, has approved Winrevair therapy of Merck & Co., Inc., to.

Read More
Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio — a transaction expected to close by the middle of this year.
Drugs Health Pharma

Merck to buy Harpoon for $680 million to step up cancer portfolio

HQ Team January 8, 2024: Merck & Co., will acquire Harpoon Therapeutics, Inc., for $680 million to expand its cancer drug portfolio —.

Read More